

June 2025 Content Release Notes

June 26, 2025

Contents

Problem Groups.....	2
Additions.....	2
Problems.....	4
Additions.....	4
Lab Analytes & Panels	4
Additions.....	4
Medications.....	7
Additions.....	7
Updates.....	8
Regimen Library.....	11
Additions.....	11
Updates.....	12
Renames.....	13
Billing & HCPCS Codes	13
Updates.....	13
Removals	16
NDC – HCPCS Crosswalk	17
Updates.....	17
Additions.....	17
Removals	17

Problem Groups

Additions

The **Problems > Add Details** area is updated with applicable documentation points for the following diagnoses.

c-Met overexpression status is now available for **Lung Cancer, Non-small cell (NSCLC)** with the following documentation points:

- 3+ intensity AND $\geq 50\%$
- $<3+$ intensity OR $<50\%$
- Unknown

CD30 status has been updated for **Lymphoma, Hodgkin (HL) and Lymphoma, Non-Hodgkin (NHL) (Parent)** with the following documentation points:

- Positive
- Negative
- Unknown

ERBB2 (HER2) is no longer available for documentation in **Colon and Rectal Cancers**.

Germline VHL alteration status has been updated for **Neuroendocrine Tumor, Carcinoid (Parent) and Renal Cell Carcinoma (RCC)** with the following documentation points:

- Pathogenic, or likely pathogenic
- Negative
- Variant of uncertain significance
- Unknown

HLA-A*02.01 status has been updated for **Melanoma, Uvea, Ciliary Body/Choroid** with the following documentation points:

- Positive
- Negative
- Unknown

HRRm/HRD (non-BRCA) status has been updated for **Prostate Cancer** with the following documentation points:

- Positive
- Negative
- Unknown

Homologous recombination (HR) status has been updated for **Fallopian Tube and Ovarian and Primary Peritoneal Cancers** with the following documentation points:

- Deficient
- Proficient
- Other non-actionable finding
- Unknown

IDH1 status has been updated for **Bile Duct Cancer (Parent), Gallbladder Cancer, Leukemia, Acute Myeloid (AML), and Myelodysplastic Syndrome (MDS)** with the following documentation points:

- Mutation
- Wild type
- Other non-actionable finding
- Unknown

KRAS status is now available for **Fallopian Tube Cancer and Ovarian and Primary Peritoneal Cancer** with the following documentation points:

- KRAS G12C mutation
- Other KRAS mutation
- Wild type
- Unknown

Oncotype Dx Recurrence Score has been updated for **Breast Cancer** with the following documentation points:

- < or = 15
- 16-25
- > or = 26
- Unknown

PALB2 status has been updated for **Pancreatic Cancer** with the following documentation points:

- Mutation
- Wild type
- Unknown

t(11;14) translocation status has been updated for **Leukemia, Chronic Lymphocytic (CLL), Lymphoma, Non-Hodgkin (NHL), CLL/SLL, and Plasma Cell Disorder (Parent)** with the following documentation points:

- Positive
- Negative
- Unknown

Problems

Additions

New items are available for documentation in **Problems** and appear in the **Charge Capture Report (CCR)**. Additional ICD-10 codes may be displayed to present the surrounding nodes.

Lab Analytes & Panels

Additions

- 2,3 bisphosphoglycerate mutation panel
- Add-on preliminary-evidence colorectal cancer guidelines genes; Invitae hereditary colorectal cancer guidelines-based panel; Invitae multi-cancer panel
- Amikacin, peak, mg/L
- AMPA-R Ab CBA, CSF
- Amphiphysin Ab, CSF
- Aspergillus glaucus IgG
- Aspergillus nidulans IgG
- Aspergillus terreus IgG
- BCL-1 t(11;14) by PCR panel
- BPGMM gene sequencing result
- BPGMM interpretation
- CASPR2-IgG CBA, CSF
- CFBF-MYH11(INV16) panel
- Chromosome analysis, cyto bone marrow additional information
- CLL FISH, bone marrow panel
- CLL, blood panel
- CLL-FISH blood NeoType panel

- ClonoSEQ - adaptive coordinates specimen retrieval (id only) panel
- ClonoSEQ - blood in EDTA (includes MRD and/or ID tests) panel
- ClonoSEQ - ctDNA- blood in streck (DLBCL only; includes MRD and/or ID tests) panel
- ClonoSEQ - fresh bone marrow (includes MRD and/or ID tests) panel
- Compass select without flow cytometry with clonoSEQ panel
- Compass select without flow cytometry without clonoSEQ panel
- Copper, plasma and RBC panel
- Copper, plasma, ug/mL
- CXC R4 mutation panel
- Cyclic citrullinated peptide (CCP) antibodies, IgA, IgG panel
- DPPX Ab CBA, CSF
- DPPX AB CBA, S
- Encephalopathy, autoimmune/paraneoplastic evaluation, CSF panel
- Encephalopathy, autoimmune/paraneoplastic evaluation, serum panel
- Encephalopathy, interpretation, CSF
- FIB-4 index panel with reflex to enhanced liver fibrosis (ELF) score panel
- FLCN panel
- Flow cytometry, bone marrow panel
- Flow cytometry, peripheral blood panel
- Foundation Medicine IHC Only panel
- GABA-B-R Ab CBA, CSF
- GAD65, CSF – nmol/L
- Ganglioside antibodies interpretation
- GFAP IFA, CSF
- Guardant Hereditary Cancer panel
- HEMP EPOR gene sequencing result
- HEMP HIF2A gene sequencing result
- HEMP molecular interpretation
- HEMP PHD2 gene sequencing result
- HEMP reviewed by
- Hereditary erythrocytosis gene panel, next-generation sequence (HEMP) panel
- Herpes simplex virus (HSV) and varicella zoster virus (VZV) panel
- Hgb A2 reflex to HPLC
- HLA B58:01, allopurinol hypersensitivity panel
- HNA antibodies
- HNA antibodies clinical relevance
- HNA antibodies electronic signature

- HNA antibodies electronic signature
- HNA antibodies methodology
- HNA antibodies panel
- HNA antibodies reference
- HPV, low risk by ISH
- HPV, low risk comment
- HTLV I/II, qualitative panel
- Human transforming growth factor beta1 (TGF-B1), pg/mL
- IFA notes, CSF
- IgLON5 CBA, CSF
- IgVH bone marrow panel
- IGVH mutation specimen status
- Invitae MUTYH panel
- JAK2 exon 12 mutation indications
- JAK2 mutation (V617F) analysis, plasma-based, Leumeta panel, quan
- JAK2 V617F mutation analysis panel, qual
- Leukemia /lymphoma clinical information
- Leukemia /lymphoma clinical information
- Leukemia /lymphoma final diagnosis
- Leukemia /lymphoma final diagnosis
- Leukemia /lymphoma flow cell population data
- Leukemia /lymphoma flow cell population data
- Leukemia /lymphoma flow disclaimer
- Leukemia /lymphoma flow disclaimer
- Leukemia /lymphoma interpretation-FC
- Leukemia /lymphoma interpretation-FC
- Leukemia/lymphoma report header
- Leukemia/lymphoma report header
- LGI1- IgG CBA, CSF
- Lymphoid NGS panel
- mGluR1 Ab IFA, CSF
- Microalbumin, random urine panel
- MPN FISH, global only panel
- MPN FISH, tech panel
- Multiple myeloma FISH, global panel
- Multiple myeloma FISH, tech panel
- MXD#, 10x3/uL

- Neo Comprehensive - heme cancers DNA ONLY panel
- Neo Comprehensive-myeloid disorders panel
- NeoType MDS/CMML panel
- Neurochondrin IFA, CSF
- Neurochondrin IFA, S
- NIF IFA, CSF
- NIF IFA, S
- NMDA-R Ab CBA, CSF
- PCA-2, CSF
- PDE10a Ab IFA, CSF
- PhenoSense GT plus integrase genotype results
- PhenoSense GT plus integrase phenotype results
- Protein Electrophoresis
- REVE2, erythrocytosis evaluation panel
- REVE2, erythrocytosis interpretation
- Rubella Ab IgG panel
- S-100B protein, serum panel
- S-100B protein, serum, ng/L
- Septin-7 IFA, CSF
- Septin-7 IFA, S
- SPE
- SPEP
- TRIM46 Ab IFA, CSF
- TRIM46 AB IFA, S

Medications

Additions

- BGB-43395 invest Oral
- BI 770371 invest IV
- BNT324/DB-1311 invest IV
- Necitumumab IV
- ONO-4578 invest Oral
- PDS0101 (3.0 mg Versamune and 2.7 mg HPVmix) invest Subcutaneous
- PF-07248144 invest Oral
- PT199 invest IV

- RLY-2608 invest Oral
- TSC-202-A0201 invest IV
- TUB-040 invest IV
- ZL-1310 invest IV

Updates

Medications	Updates
<p>Avutometinib Oral</p>	<p>Old Instructions removed:</p> <ul style="list-style-type: none"> • Avutometinib 3.2 mg orally 2 times per week for 3 wks; take twice weekly on days 1 and 4 during weeks 1 through 3 of each 4-week cycle; per protocol with defactinib <p>New Instructions available:</p> <ul style="list-style-type: none"> • avutometinib 3.2 mg orally 2 times per week; Take 2x/week on days 1 and 4 during weeks 1 through 3 of each 4-week cycle; per protocol with defactinib • avutometinib 3.2 mg orally As Directed • avutometinib 3.2 mg orally Per package directions • avutometinib 2.4 m.g orally 2 times per week; Take 2x/week on days 1 and 4 during weeks 1 through 3 of each 4-week cycle; per protocol with defactinib • avutometinib 2.4 mg orally As Directed • avutometinib 2.4 mg orally Per package directions • Take with food.
<p>avutometinib-defactinib Combo Pack 0.8 mg-200 mg</p>	<p>Old Instructions removed:</p> <ul style="list-style-type: none"> • AVUTOMETINIB: take 4 capsules by mouth once daily on days 1 and 4 during weeks 1-3; DEFACTINIB: take 1 tablet by mouth twice daily during weeks 1-3 <p>New Instructions available:</p> <ul style="list-style-type: none"> • Take with food.
<p>AZD2936 invest IV</p>	<p>New Alias available:</p> <ul style="list-style-type: none"> • Rilvegostomig invest

Medications	Updates
Fakzinja (defactinib Oral)	New Maximum Single Dose available: <ul style="list-style-type: none"> • 200 mg New Instructions available: <ul style="list-style-type: none"> • Take 2x/day during weeks 1 through 3 of each 4-week cycle; per protocol with avutometinib. Take with food.
Ferric Derisomaltose IV	New BSA Weight of 50 kg available for the following SIGs: <ul style="list-style-type: none"> • Ferric Derisomaltose 20 mg/kg intravenously Piggyback once • Ferric Derisomaltose 20 mg/kg intravenously once
MK-2870 invest IV	New Alias available: <ul style="list-style-type: none"> • Sacituzumab tirumotecan invest New Quick SIG Options available: <ul style="list-style-type: none"> • 24 mg/kg intravenously every 2 weeks; Final concentration 0.5-5.0. Administer over 90 minutes (+/- 15 minutes) • 3 mg/kg intravenously once
MRTX1719 invest Oral	New Form available: <ul style="list-style-type: none"> • 50 mg tablet
Necitumumab IV	Medication has been Reactivated .
ocrelizumab-hyaluronidase-ocsq Subcutaneous 920 mg-23,000 unit/23 mL	New Quick SIG Options available: <ul style="list-style-type: none"> • 0 mg subcutaneously once

Medications	Updates
<p>ocrelizumab-hyaluronidase-ocsq Subcutaneous 920 mg-23,000 unit/23 mL</p>	<p>New Maximum Single Dose available:</p> <ul style="list-style-type: none"> • 920 mg <p>New default SIG available:</p> <ul style="list-style-type: none"> • 920 mg subcutaneously once <p>New Route available:</p> <ul style="list-style-type: none"> • Via continuous subcutaneous infusion <p>New Instructions available:</p> <ul style="list-style-type: none"> • FOR SUBCUTANEOUS ADMINISTRATION ONLY. Administer into the abdomen over 10 minutes using a subcutaneous infusion set containing a 24-26G needle and a priming volume 0.8 mL or less. Do NOT administer within 2 inches around the navel or into areas where the skin is red, bruised, tender, hard, or areas where there are moles or scars. Do NOT dilute or shake. Do NOT administer remaining priming volume after ocrelizumab-hyaluronidase-ocsq. Monitor patients during all injections and for at least one hour after the initial injection and for at least 15 minutes after subsequent injections. NOTE: This is Ocrevus Zunovo.
<p>PF-06821497 invest Oral</p>	<p>New Alias available:</p> <ul style="list-style-type: none"> • Mevrometostat invest <p>New Quick SIG Options available:</p> <ul style="list-style-type: none"> • 625 mg orally 2 times per day • 750 mg orally 2 times per day • 875 mg orally 2 times per day
<p>Rilvegostomig invest IV</p>	<p>Set inactive. Available Replacement:</p> <ul style="list-style-type: none"> • AZD2936 invest IV • Rilvegostomig invest (AZD2936 invest IV)

Medications	Updates
telisotuzumab vedotin-tllv IV	<p>New Maximum Single Dose available:</p> <ul style="list-style-type: none"> • 190 mg <p>New BSA Override with Weight available:</p> <ul style="list-style-type: none"> • 100 kg <p>New Instructions available:</p> <ul style="list-style-type: none"> • Dilute in NS to achieve a final concentration of 1 to 10 mg/mL. Gently invert to mix. Do not shake. Administer using a dedicated infusion line and 0.2 or 0.22-micron in-line polyether sulfone, polyvinylidene fluoride, or polyamide filter. Do not mix or administer with other drugs. NOTE: Telisotuzumab vedotin-tllv is a possible irritant.
TT-00420 invest Oral	<p>New Alias available:</p> <ul style="list-style-type: none"> • Tinengotinib invest

Regimen Library

Additions

Regimen Name	Diagnosis
Avutometinib + Defactinib Q28D	Fallopian Tube Cancer; Ovarian and Primary Peritoneal Cancer
Nipocalimab-aahu IV Q14D	Myasthenia Gravis
Ocrelizumab-hyaluronidase-ocsq Q6M	Multiple Sclerosis
Pembrolizumab (Dose Banding) + Lenvatinib Q42D Dose Optimization	Uterine Cancer (Parent)
Pembrolizumab (Flat Dose) + Paclitaxel D1,8,15,22,29,36 + Carboplatin D1,8,15,22,29,36 Q42D fb Pembrolizumab (Flat Dose) + Doxorubicin + Cyclophosphamide (AC) D1,15,29 Q42D Dose Dense	Breast Cancer

Regimen Name	Diagnosis
Pembrolizumab (Flat Dose) + Paclitaxel D1,8,15,22,29,36 + Carboplatin D1,22 Q42D fb Pembrolizumab (Flat Dose) + Doxorubicin + Cyclophosphamide (AC) D1,15,29 Q42D Dose Dense	Breast Cancer
Pembrolizumab + Lenvatinib Q21D Dose Optimization	Uterine Cancer (Parent)
Pembrolizumab + Lenvatinib Q42D Dose Optimization	Uterine Cancer (Parent)
Telisotuzumab vedotin-tllv (Emrelis) Q14D	Lung Cancer, Non-small Cell (NSCLC)

Updates

Regimens for the following diagnoses have been updated based on the Collaborative Care Committee voting. Changes include but are not limited to reference update, drug infusion instruction updates, renaming of regimens, premedication template updates and number of cycles.

- Anal Cancer (Parent)
- Bile Duct Cancer (Parent)
- Bladder Cancer
- Breast Cancer
- Cervical Cancer
- Colon Cancer
- Esophageal Cancer (Parent)
- Gallbladder Cancer
- Gastric Cancer
- Head and Neck Cancer (Parent)
- Leukemia, Chronic Lymphocytic (CLL)
- Lymphoma, Hodgkin (HL)
- Melanoma, Skin
- Neuroendocrine Tumor, Carcinoid (Parent)
- Pancreatic Cancer
- Pancreatic Cancer, Carcinoid/Neuroendocrine
- Rectal Cancer
- Renal Cell Carcinoma (RCC)
- Renal Pelvis and Ureter Cancer
- Urethral Cancer

Renames

Previous Name	New Name
Nivolumab (3 mg/kg) + Ipilimumab (1 mg/kg) Q21D	Nivolumab (3 mg/kg) + Ipilimumab (1 mg/kg) C1 D1,22,43,64 (Q21D) followed by Nivolumab C2+ D1,29,57 (Q28D) Maintenance Q84D

Billing & HCPCS Codes

Updates

The July 2025 updates include new HCPCS Level II codes to separately identify products approved under the 505(b)(2) New Drug Application (NDA) or the Biologics License Applications (BLA) pathways after October 2003 and not rated as therapeutically equivalent to a reference listed product in an existing code. A complete application summary and coding link can be found on the CMS website.

Please visit CMS's website for a complete list of July 2025 HCPCS Quarterly update.

The following products have **not been released**, per First Databank (FDB):

- J9174 - docetaxel (beizray)
- J9274 - cosibelimab-ipdl
- Q5098 - ustekinumab-srlf (imuldosa)
- Q5153 - aflibercept-yszy (opuviz)

Additions

Medication	HCPCS Codes
telisotuzumab vedotin-tllv IV	J9999 per 100 mg
atezolizumab-hyaluronidase-tqjs Subcutaneous 1,875 mg-30,000 unit/15 mL	J9024 per 15 mL
aztreonam-avibactam IV 2 gram	J3490 per 2 g
denosumab-bbdz Subcutaneous (60 mg/mL - Jubbonti)	Q5136 per 1 mg
efbemalenograstim alfa-vuxw Subcutaneous	J9361 per 0.5 mg
mening vac A,C,Y,W135,tet (PF) IM 10 mcg/0.5 mL	90619 per 0.5 mL

Medication	HCPSC Codes
nipocalimab-aahu IV	J3590 per 185 mg

The following HCPSC codes will be effective July 1, 2025.

Medication	HCPSC Codes
Atidarsagene autotemcel IV	J3391 per tx
Calcium Chloride IV	J0618 per 2 mg
Diltiazem IV	J1163 per 0.5 mg
Epinephrine (PF) IM	J0165 J0166 J0167 per 0.1 mg J0168 J0169
Epinephrine (PF) IV	J0165 J0166 J0167 per 0.1 mg J0168 J0169
Epinephrine (PF) Subcutaneous	J0165 J0166 J0167 per 0.1 mg J0168 J0169
Epinephrine IM	J0165 J0166 J0167 per 0.1 mg J0168 J0169
Epinephrine IM Pen Injector 0.15 mg/0.3 mL (1:2,000) (Ped)	J0165 J0166 J0167 per 0.1 mg J0168 J0169
Epinephrine IM Pen Injector 0.3 mg/0.3 mL (1:1,000) (Adult)	J0165 J0166 J0167 per 0.1 mg J0168 J0169

Medication	HCPSC Codes
Epinephrine IV	J0165 J0166 J0167 per 0.1 mg J0168 J0169
Epinephrine Subcutaneous	J0165 J0166 J0167 per 0.1 mg J0168 J0169
Epinephrine Subcutaneous Pen Injector 0.15 mg/0.3 mL (1:2,000) (Ped)	J0165 J0166 J0167 per 0.1 mg J0168 J0169
Epinephrine Subcutaneous Pen Injector 0.3 mg/0.3 mL (1:1,000) (Adult)	J0165 J0166 J0167 per 0.1 mg J0168 J0169
Foscarbidopa-foslevodopa Continuous Subcutaneous Infusion	J7356 per 5 mg
Foscarbidopa-foslevodopa Subcutaneous	J7356 per 5 mg
Indigotindisulfonate IV	J9220 per: 1 mg 0.125 mL
Marstacimab-hncq Subcutaneous Pen Injector	J7172 per 0.5 mg
Metoprolol IV	J0616 per 1 mg
Naloxone IM	J2312 per 0.01 mg J2313 per 0.01 mg
Naloxone IM Auto-Injector	J2312 per 0.01 mg
Naloxone IV	J2312 per: 0.01 mg 10 mcg
Naloxone Subcutaneous	J2312 per 0.01 mg J2313 per 0.01 mg
Naloxone Subcutaneous Auto-Injector	J2312 per 0.01 mg

Medication	HCPSC Codes
nivolumab-hyaluronidase-nvhy Subcutaneous 600 mg-10,000 unit/5 mL	J9289 per: 2 mg 0.016667 mL
Obecabtagene autoleucl IV	Q2058 per 400 x 10e6 CARpos viable T cells
Thiotepa IM	J9342 per 1 mg
Thiotepa IV	J9341 per 1 mg J9342 per 1 mg
Ustekinumab-kfce IV	Q5100 per 1 mg
Ustekinumab-kfce Subcutaneous	Q5100 per 1 mg
Ustekinumab-stba IV	Q5099 per 1 mg
Ustekinumab-stba Subcutaneous	Q5099 per 1 mg
Vancomycin IV	J3373 J3374 per 10 mg & 0.01 g J3375
Zanidatamab-hrii	J9276 per 2 mg
Zenocutuzumab-zbco IV	J9382 per 1 mg
Zolbetuximab-clzb IV	J1326 per 2 mg

Removals

The following HCPSC codes will be discontinued on June 30, 2025.

Medication	HCPSC Codes
Naloxone IM	J2310 per 1 mg J2311 per 1 mg
Naloxone IM Auto-Injector	J2310 per 1 mg
Naloxone IV	J2310 per 1 mg
Naloxone Subcutaneous	J2310 per 1 mg J2311 per 1 mg
Naloxone Subcutaneous Auto-Injector	J2310 per 1 mg
Thiotepa IM	J9340 per 15 mg
Thiotepa IV	J9340 per 15 mg
Vancomycin IV	J3370 J3371 per 500 mg J3372

NDC – HCPCS Crosswalk

Updates

The CMS ASP pricing can be found at the following website:
<https://www.cms.gov/medicare/payment/part-b-drugs/asp-pricing-files>

Additions

The following HCPCS codes and NDCs will be effective July 1, 2025.

Medication (Brand)	HCPCS Codes	NDC
Naloxone IM (Zimhi)	J2313 per 0.01 mg	78670014002, 78670014011
Naloxone Subcutaneous (Zimhi)	J2313 per 0.01 mg	78670014002, 78670014011
Vancomycin IV (Mylan)	J3374 per 10 mg	67457070500, 67457070575, 67457082225, 67457082299, 67457082312, 67457082399, 67457082415, 67457082499, 72078006550, 72078006599, 72078006650, 72078006699
Vancomycin IV (Xellia)	J3375 per 10 mg	70594004101, 70594004103, 70594004201, 70594004203, 70594004301, 70594004302, 70594004401, 70594004402, 70594005601, 70594005603, 70594005701, 70594005702, 70594005801, 70594005802
Thiotepa IV (Tepylute)	J9341 per 1 mg	81927010601, 81927010501

Removals

The following HCPCS codes and NDCs will be discontinued on June 30, 2025:

Medication (Brand)	HCPCS Codes	NDC
Naloxone IM (Zimhi)	J2311 per 0.01 mg	78670014002, 78670014011
Naloxone Subcutaneous (Zimhi)	J2311 per 0.01 mg	78670014002, 78670014011

Medication (Brand)	HCPCS Codes	NDC
Vancomycin IV (Mylan)	J3371 per 500 mg	67457070500, 67457070575, 67457082225, 67457082299, 67457082312, 67457082399, 67457082415, 67457082499, 72078006550, 72078006599, 72078006650, 72078006699
Vancomycin IV (Xellia)	J3372 per 500 mg	70594004101, 70594004103, 70594004201, 70594004203, 70594004301, 70594004302, 70594004401, 70594004402, 70594005601, 70594005603, 70594005701, 70594005702, 70594005801, 70594005802